Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015 Is Released Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan 1
mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179108/refractory-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179108/refractory-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9 Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Refractory Chronic Lymphocytic Universities/Institutes 13
Leukemia
(CLL)
-
Therapeutics
under
Investigation
by
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17
2
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20 Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21 4SC AG 21 AbbVie Inc. 22 Astellas Pharma Inc. 23 Astex Pharmaceuticals, Inc. 24 AstraZeneca Plc 25 Boehringer Ingelheim GmbH 26 Bristol-Myers Squibb Company 27 Celgene Corporation 28 Cellular Biomedicine Group, Inc. 29 F. Hoffmann-La Roche Ltd. 30 Hutchison MediPharma Limited 31 ImmunoGen, Inc. 32 Immunomedics, Inc. 33 Incyte Corporation 34 Infinity Pharmaceuticals, Inc. 35 Innate Pharma SA 36 Juno Therapeutics Inc. 37 Karyopharm Therapeutics, Inc. 38 Les Laboratoires Servier SAS 39 LFB S.A. 40 Lymphocyte Activation Technologies, S.A. 41 3
Medicenna Therapeutics, Inc 42 MedImmune, LLC 43 Millennium Pharmaceuticals, Inc. 44 MorphoSys AG 45 Novartis AG 46 Ono Pharmaceutical Co., Ltd. 47 Portola Pharmaceuticals, Inc. 48 Sanofi 49 TG Therapeutics, Inc. 50 Threshold Pharmaceuticals, Inc. 51 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 57 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 (INCB-039110 + INCB-040093) - Drug Profile 64 4SC-202 - Drug Profile 65 acalabrutinib - Drug Profile 67 ACP-319 - Drug Profile 70 afuresertib hydrochloride - Drug Profile 71 AGS-67E - Drug Profile 73 4
AT-7519 - Drug Profile 74 AZD-6738 - Drug Profile 77 BI-836826 - Drug Profile 79 BMS-986016 - Drug Profile 80 buparlisib hydrochloride - Drug Profile 81 CBM-C19.1 - Drug Profile 85 CBM-C20.1 - Drug Profile 86 CC-122 - Drug Profile 88 Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 90 Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 91 cerdulatinib - Drug Profile 92 duvelisib - Drug Profile 93 evofosfamide - Drug Profile 96 HMPL-523 - Drug Profile 104 IMGN-529 - Drug Profile 105 IMMU-114 - Drug Profile 107 inebilizumab + rituximab - Drug Profile 108 IPH-2201 - Drug Profile 109 JCAR-014 - Drug Profile 111 JCAR-015 - Drug Profile 112 lirilumab - Drug Profile 114 MDNA-56 - Drug Profile 116 MOR-208 - Drug Profile 117 5
nivolumab - Drug Profile 119 obinutuzumab - Drug Profile 126 pilaralisib - Drug Profile 129 S-055746 - Drug Profile 132 selinexor - Drug Profile 133 spebrutinib besylate - Drug Profile 138 TAK-659 - Drug Profile 140 TGR-1202 - Drug Profile 141 tisagenlecleucel-T - Drug Profile 143 trametinib dimethyl sulfoxide - Drug Profile 146 ublituximab - Drug Profile 149 ublituximab + TGR-1202 - Drug Profile 151 UC-961 - Drug Profile 152 ulocuplumab - Drug Profile 153 urelumab - Drug Profile 155 venetoclax - Drug Profile 157 Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 160 Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 248 Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 249 Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 250 Featured News & Press Releases 250 Appendix 259 Methodology 259 6
Coverage 259 Secondary Research 259 Primary Research 259 Expert Panel Validation 259 Contact Us 259 Disclaimer 260" width="80" height="40" />Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Read More http://www.idatainsights.com/reports-landing-page.php?id=179108/refractory-chroniclymphocytic-leukemia-cll-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship 7
with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
8